Native VIP itself has no FDA approval; a synthetic analogue (aviptadil) holds FDA Fast Track/Orphan Drug designation for acute lung injury but is not itself approved in the US.
VIP binds VPAC1 and VPAC2, class B G-protein-coupled receptors that classically activate adenylate cyclase and raise intracellular cAMP. Through this signaling it modulates neural, gastrointestinal, i...
VIP binds VPAC1 and VPAC2, class B G-protein-coupled receptors that classically activate adenylate cyclase and raise intracellular cAMP. Through this signaling it modulates neural, gastrointestinal, immune, endocrine, and circadian processes; in pancreatic beta cells, VPAC2 activation triggers cAMP/PKA-mediated closure of ATP-sensitive potassium channels and subsequent insulin secretion, and VIP has also been studied as an endogenous anti-inflammatory neuropeptide that helps maintain immune tolerance.
Frontiers in Endocrinology · 2022
Reviews evidence that VIP stimulates insulin secretion via VPAC2 receptor activation and discusses VPAC2-selective agonists as potential diabetes therapeutics.
View Source →Peptides · 2007
Describes VIP as an endogenous anti-inflammatory neuropeptide that maintains immune tolerance by inducing regulatory T cells that suppress autoreactive effector cells.
View Source →Journal of Biological Chemistry · 2000
Mutagenesis of VIP identified residues critical for VPAC1 binding, and produced a VIP analogue over 1,000-fold selective for VPAC1 over VPAC2.
View Source →